PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mizolastine→

Mizolastine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
108612-45-9
Molecular formula
C24H25FN6O
Molecular weight
432.5 g/mol
Drug class
Second-generation, long-acting histamine H1-receptor antagonistantihistamine
Mechanism of action
Selectively antagonises peripheral histamine H1 receptors, reducing histamine-mediated allergic symptoms. It has limited penetration into the central nervous system and relatively low sedative activity at therapeutic doses.
Indications / reported uses
  • Symptomatic relief of seasonal and perennial allergic rhinoconjunctivitis, including hay fever.
  • Symptomatic treatment of urticaria.

Sources: https://patient-info.co.uk/mizollen-10-mg-modified-release-tablets-94743/summary-of-medicine-characteristics · https://www.ncbi.nlm.nih.gov/mesh/?term=mizolastine

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Mizolastine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mizolastine Permitted Daily Exposure (PDE) report (the Mizolastine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mizolastine Occupational Exposure Limit (OEL) report (the Mizolastine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.